Masimo (MASI)
(Delayed Data from NSDQ)
$106.44 USD
-1.65 (-1.53%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $106.33 -0.11 (-0.10%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$106.44 USD
-1.65 (-1.53%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $106.33 -0.11 (-0.10%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth D Momentum C VGM
Zacks News
Masimo Gets FDA Nod for Rad-97, Enables Healthcare at Home
by Zacks Equity Research
Masimo (MASI) states that with its inherent touchscreen interface, Rad-97 is user-friendly for clinicians and non-clinicians and can be easily tailored to cater to the needs of home users.
Cogentix (CGNT) Stock Near 52-Week High: More Room to Run?
by Zacks Equity Research
Cogentix Medical (CGNT) stock continues to hover around the 52-week high mark reached on Dec 27, courtesy of its new strategies.
Robust Pipeline Aids Edwards Lifesciences, Rising Costs Ail
by Zacks Equity Research
Edwards Lifesciences' (EW) pipeline building to fortify foothold across all operating businesses bodes well. Also, the TAVR adoption rate across Japan and the European countries is impressive.
Align Rides on Balanced Segmental Growth Amid Stiff Contest
by Zacks Equity Research
Align (ALGN) gains from balanced sales growth across all its channels of late, primarily on high InvisAlign Technology case volumes.
Here's Why You Should Invest in Masimo (MASI) Right Now
by Zacks Equity Research
Masimo (MASI) rides high on its solid guidance. The company's recent FDA approval is also encouraging.
The Zacks Analyst Blog Highlights: IDEXX Laboratories, Luminex, Masimo, Align Technology and Cooper Companies
by Zacks Equity Research
The Zacks Analyst Blog Highlights: IDEXX Laboratories, Luminex, Masimo, Align Technology and Cooper Companies
5 MedTech Stocks to Beat Tax Hazards With Positive Returns
by Zacks Equity Research
Trump's tax reform policies promise to cut corporate taxes. However, the future of the U.S. MedTech industry depends on the much-awaited decision on the 2.3% medical device tax.
Here's Why You Should Invest in Masimo (MASI) Right Now
by Zacks Equity Research
Masimo (MASI) continues to grow on innovation and product launches.
Masimo (MASI) Beats on Q3 Earnings and Revenues, Raises View
by Zacks Equity Research
Masimo (MASI) raises fiscal 2017 guidance. The year-over-year increase in both revenues and earnings encourages.
Masimo (MASI) Launches Trace Data and Reporting Tool in US
by Zacks Equity Research
Masimo's (MASI) launch of Trace in the United States will aid the company in capturing the growing patient data visualization market.
AmerisourceBergen's PharMEDium Slows Down, Competition Rife
by Zacks Equity Research
AmerisourceBergen'S (ABC) growth story is expected to be stunted by tepid performance at PharMEDium. Also steep competition is a cause of concern.
Amedisys' Arm Buys Intercity Home Care, Boosts U.S. Base
by Zacks Equity Research
Amedisys' (AMED) encouraging efforts put the Personal Care business on growth track. This segment lives up to a strong performance with the integration of several recent tuck-in acquisitions.
Abbott to Gain from Alere's Takeover Due for Oct 3 Closure
by Zacks Equity Research
Alere's acquisition would help Abbott (ABT) explore new channels and geographies, including forays into fast growing outlets like doctors' offices, clinics, pharmacies and at-home testing.
Masimo RAS-45 Full-Market Release to Boost Respiratory Care
by Zacks Equity Research
Masimo Corporation's (MASI) newly launched RAS-45, a single use adhesive respiration sensor would strengthen the company's foothold in the growing global respiratory care market.
Here's Why Investors Should Buy Masimo (MASI) Right Now
by Zacks Equity Research
Masimo (MASI) announced 510(k) clearance and full-market release of its proprietary Rad-97 Pulse CO-Oximeter earlier this month.
The Zacks Analyst Blog Highlights: Cardinal Health, Penumbra, STAAR Surgical, Masimo and Smith & Nephew
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cardinal Health, Penumbra, STAAR Surgical, Masimo and Smith & Nephew
Top MedTech Stocks Safe from Graham-Cassidy Repeal Bill
by Zacks Equity Research
The investment climate for medical device majors has become increasingly volatile due to political potshots in Capitol Hill, for and against Obamacare.
Republicans Take Last Shot at Obamacare: 5 MedTech Stocks to Buy
by Zacks Equity Research
The fate of Obamacare will be decided on Sep. 30. No matter what the future holds, the day will provide investors a clear picture of where the MedTech industry is headed.
Masimo (MASI) Launches Rad-97 CO-Oximeter Post FDA Clearance
by Zacks Equity Research
Masimo's (MASI) newly-launched Rad-97 Pulse CO-Oximeter will strengthen the company's presence in the Advanced Monitoring Technologies space.
5 Discounted MedTech Stocks for a Healthy Portfolio
by Zacks Equity Research
In view of the current political scenario and banking on favorable metrics, these five MedTech stocks stand out as the most suitable value picks.
Why Is Masimo (MASI) Down 1.5% Since the Last Earnings Report?
by Zacks Equity Research
Masimo (MASI) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ride Out MedTech Volatility With These 3 Ultra-Safe Stocks
by Zacks Equity Research
In view of the current political scenario and banking on favorable metrics, these three low-beta MedTech stocks stand out as the most suitable value picks.
3 Excellent Value Picks as Political Chaos Grips MedTech
by Zacks Equity Research
In view of the current political scenario and banking on favorable metrics, these three MedTech stocks stand out as the most suitable value picks.
Zacks.com featured highlights: CBRE Group, East West Bancorp, Hasbro, Canadian Pacific Railway and Masimo
by Zacks Equity Research
Zacks.com featured highlights: CBRE Group, East West Bancorp, Hasbro, Canadian Pacific Railway and Masimo
5 GARP Stocks to Buy for Marvelous Returns
by Zacks Equity Research
GARP helps an investor gain exposure to stocks that are undervalued and have impressive prospects.